CN114891798B - T细胞受体基因修饰小鼠 - Google Patents

T细胞受体基因修饰小鼠

Info

Publication number
CN114891798B
CN114891798B CN202210507387.4A CN202210507387A CN114891798B CN 114891798 B CN114891798 B CN 114891798B CN 202210507387 A CN202210507387 A CN 202210507387A CN 114891798 B CN114891798 B CN 114891798B
Authority
CN
China
Prior art keywords
human
tcr
segment
unrearranged
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210507387.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN114891798A (zh
Inventor
L·麦克唐纳
A·J·莫菲
J·麦克沃克
N·图
V·沃罗宁那
C·古雷尔
K·梅格尔
S·史蒂文斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CN114891798A publication Critical patent/CN114891798A/zh
Application granted granted Critical
Publication of CN114891798B publication Critical patent/CN114891798B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0387—Animal model for diseases of the immune system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN202210507387.4A 2011-10-28 2012-10-26 T细胞受体基因修饰小鼠 Active CN114891798B (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201161552582P 2011-10-28 2011-10-28
US61/552,582 2011-10-28
US201261621198P 2012-04-06 2012-04-06
US61/621,198 2012-04-06
US201261700908P 2012-09-14 2012-09-14
US61/700,908 2012-09-14
CN201280064216.3A CN104011071B (zh) 2011-10-28 2012-10-26 T细胞受体基因修饰小鼠
PCT/US2012/062065 WO2013063361A1 (en) 2011-10-28 2012-10-26 Genetically modified t cell receptor mice

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280064216.3A Division CN104011071B (zh) 2011-10-28 2012-10-26 T细胞受体基因修饰小鼠

Publications (2)

Publication Number Publication Date
CN114891798A CN114891798A (zh) 2022-08-12
CN114891798B true CN114891798B (zh) 2025-12-02

Family

ID=47178340

Family Applications (5)

Application Number Title Priority Date Filing Date
CN202210507387.4A Active CN114891798B (zh) 2011-10-28 2012-10-26 T细胞受体基因修饰小鼠
CN201710930556.4A Active CN107858333B (zh) 2011-10-28 2012-10-26 T细胞受体基因修饰小鼠
CN201710930555.XA Pending CN107858332A (zh) 2011-10-28 2012-10-26 T细胞受体基因修饰小鼠
CN202210507359.2A Pending CN114891797A (zh) 2011-10-28 2012-10-26 T细胞受体基因修饰小鼠
CN201280064216.3A Active CN104011071B (zh) 2011-10-28 2012-10-26 T细胞受体基因修饰小鼠

Family Applications After (4)

Application Number Title Priority Date Filing Date
CN201710930556.4A Active CN107858333B (zh) 2011-10-28 2012-10-26 T细胞受体基因修饰小鼠
CN201710930555.XA Pending CN107858332A (zh) 2011-10-28 2012-10-26 T细胞受体基因修饰小鼠
CN202210507359.2A Pending CN114891797A (zh) 2011-10-28 2012-10-26 T细胞受体基因修饰小鼠
CN201280064216.3A Active CN104011071B (zh) 2011-10-28 2012-10-26 T细胞受体基因修饰小鼠

Country Status (25)

Country Link
US (4) US9113616B2 (https=)
EP (3) EP3795587A1 (https=)
JP (7) JP6254528B2 (https=)
KR (5) KR102321909B1 (https=)
CN (5) CN114891798B (https=)
AU (5) AU2012327204B2 (https=)
BR (1) BR112014009203B1 (https=)
CA (1) CA2853707A1 (https=)
CY (2) CY1120945T1 (https=)
DK (2) DK2771357T3 (https=)
ES (2) ES2858978T3 (https=)
HR (2) HRP20181626T1 (https=)
HU (1) HUE053444T2 (https=)
IL (4) IL305550B2 (https=)
IN (1) IN2014CN03890A (https=)
LT (2) LT3424947T (https=)
MX (2) MX353134B (https=)
PL (2) PL2771357T3 (https=)
PT (2) PT3424947T (https=)
RS (2) RS57893B1 (https=)
RU (1) RU2661106C2 (https=)
SG (2) SG11201401030WA (https=)
SI (2) SI2771357T1 (https=)
SM (2) SMT202100243T1 (https=)
WO (1) WO2013063361A1 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3424947T (lt) * 2011-10-28 2021-03-10 Regeneron Pharmaceuticals, Inc. Genetiškai modifikuotos t ląstelių receptorių pelės
US20150073043A1 (en) * 2012-01-19 2015-03-12 Institut Pasteur Of Shanghai, Chinese Academy Of Sciences Use of phosphorylation pathway-related factor in regulating function of regulatory t cell
IN2014DN09261A (https=) 2012-04-25 2015-07-10 Regeneron Pharma
GB2508414A (en) * 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
SI2986729T1 (sl) 2013-04-16 2019-02-28 Regeneron Pharmaceuticals, Inc. Ciljana sprememba genoma podgane
US9546384B2 (en) 2013-12-11 2017-01-17 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a mouse genome
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
RS60359B1 (sr) * 2014-06-06 2020-07-31 Regeneron Pharma Postupci i kompozicije za modifikovanje ciljanog lokusa
ES2783424T3 (es) * 2014-06-19 2020-09-17 Regeneron Pharma Animales no humanos que tienen un gen de muerte celular programada 1 humanizado
KR102386101B1 (ko) 2014-06-26 2022-04-14 리제너론 파마슈티칼스 인코포레이티드 표적화된 유전자 변형을 위한 방법 및 그 조성물, 및 사용 방법
CA2959428A1 (en) * 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors
ES2731437T3 (es) 2014-11-21 2019-11-15 Regeneron Pharma Métodos y composiciones para la modificación genética dirigida mediante el uso de pares de ARN guías
RU2020122439A (ru) * 2014-11-24 2020-09-24 Регенерон Фармасьютикалз, Инк. Не относящиеся к человеку животные, экспрессирующие гуманизированный комплекс cd3
KR102530821B1 (ko) 2014-12-19 2023-05-10 리제너론 파마슈티칼스 인코포레이티드 단일 단계 다중 표적화를 통한 표적화된 유전자 변형을 위한 방법 및 조성물
CN113349159B (zh) * 2015-04-06 2022-11-11 瑞泽恩制药公司 非人动物中的人源化t细胞介导的免疫应答
CN107667173A (zh) 2015-05-06 2018-02-06 斯尼普技术有限公司 改变微生物种群和改善微生物群
SG11201803409UA (en) 2015-11-20 2018-05-30 Regeneron Pharma Non-human animals having a humanized lymphocyte-activation gene 3
CN109415687A (zh) * 2016-04-07 2019-03-01 蓝鸟生物公司 嵌合抗原受体t细胞组合物
PL3440105T3 (pl) 2016-04-08 2022-08-29 Immunocore Limited Receptory komórek t
HUE061619T2 (hu) * 2016-06-03 2023-07-28 Regeneron Pharma Exogén terminális dezoxinukleotid-transzferázt expresszáló rágcsálók
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
CN110996974A (zh) 2017-06-16 2020-04-10 梅约医学教育与研究基金会 增加免疫应答的材料和方法
BR112020006643A2 (pt) 2017-10-03 2020-09-24 Juno Therapeutics Inc moléculas de ligação específica ao hpv
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
CA3094468A1 (en) * 2018-04-05 2019-10-10 Juno Therapeutics, Inc. Methods of producing cells expressing a recombinant receptor and related compositions
CN112752838A (zh) * 2018-07-26 2021-05-04 国立大学法人京都大学 制备引入外源抗原受体的细胞的方法
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
CA3154287A1 (en) * 2019-09-12 2021-03-18 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
JP7726881B2 (ja) 2019-12-02 2025-08-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ペプチド－ｍｈｃ ｉｉタンパク質構築物およびそれらの使用
AU2021244594A1 (en) * 2020-03-27 2022-12-01 Regeneron Pharmaceuticals, Inc. T cell receptors
CN113684258B (zh) 2020-05-18 2024-08-20 上海赛比曼生物科技有限公司 用于检测鼠源tcr转基因拷贝数的试剂盒及方法
AU2022249328A1 (en) 2021-03-31 2023-09-21 Regeneron Pharmaceuticals, Inc. Genetically modified mice comprising humanized cellular immune system components with improved diversity of tcrβ repertoire
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
EP4568989A2 (en) * 2022-08-12 2025-06-18 Ingenious Targeting Laboratories Genetically modified non-human having humanized gamma and delta tcr variable genes
CA3265218A1 (en) 2022-08-18 2024-02-22 Immunocore Ltd MAGE A4 SPECIFIC T LYMPHOCYTE RECEPTOR FUSION PROTEINS
IL319406A (en) * 2022-09-22 2025-05-01 Regeneron Pharma Genetically modified mice expressing components of the human cellular immune system
TW202520975A (zh) 2023-08-09 2025-06-01 英商劍橋企業有限公司 基因改造之囓齒動物及囓齒動物細胞以及其等用途
GB2640828A (en) 2024-04-22 2025-11-12 T Therapeutics Ltd Methods and products for the generation and identification of T cells and TCRs
GB2642411A (en) 2024-04-22 2026-01-14 T Therapeutics Ltd T Cell Receptor identification and provision

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002059263A2 (en) * 2000-12-19 2002-08-01 Sunol Molecular Corporation Transgenic animals comprising a humanized immune system
CN104011071A (zh) * 2011-10-28 2014-08-27 瑞泽恩制药公司 T细胞受体基因修饰小鼠

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0663952A4 (en) 1992-09-11 1997-06-11 Univ California Transgenic non-human animals having targeted lymphocyte transduction genes.
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
EP0910409A4 (en) 1996-03-05 2003-03-19 Scripps Research Inst RECOMBINANT GENE CONSTRUCTS ENCODING T-CELL RECEPTORS SPECIFIC TO HUMAN-RESTRICTED TUMORANTANTIGENS
US6320306B1 (en) * 1996-08-05 2001-11-20 Samsung Display Devices Co., Ltd. Shadow mask with porous insulating layer and heavy metal layer
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
WO2001027291A1 (en) 1999-10-12 2001-04-19 Institut Pasteur Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice
US7462486B2 (en) 2000-05-12 2008-12-09 Oregon Health & Science University Methods of selecting T cell receptor V peptides for therapeutic use
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050050580A1 (en) 2000-12-13 2005-03-03 Masashi Gotoh Transgenic animal expressing hla-a24 and utilization thereof
FR2827302B1 (fr) 2001-07-13 2003-10-10 Genoway Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations
AU2002321581C1 (en) 2001-08-31 2008-09-18 Adaptimmune Limited Soluble T cell receptor
US20050177884A1 (en) 2001-11-15 2005-08-11 Kirin Beer Kabushiki Kaisha Chimeric nonhuman animal
DK1321477T3 (da) 2001-12-22 2005-02-14 4Antibody Ag Fremgangsmåde til frembringelsen af genetisk modificerede vertebrate precursor-lymfocytter og anvendelse deraf til fremstillingen af heterologe bindende proteiner
IL162111A0 (en) 2001-12-22 2005-11-20 4Antibody Ag Method for the generation of generically modified vertebrate precursor lymphocytes and use thereof for the production of heterologo
DE10244457A1 (de) 2002-09-24 2004-04-01 Johannes-Gutenberg-Universität Mainz Verfahren zur rationalen Mutagenese von alpha/beta T-Zell Rezeptoren und entsprechend mutierte MDM2-Protein spezifische alpha/beta T-Zell Rezeptoren
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
US20060156419A1 (en) * 2002-10-30 2006-07-13 The Wistar Institute Of Anatomy And Biology Mouse model for autoimmune disorders
US7663017B2 (en) 2003-07-30 2010-02-16 Institut Pasteur Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
AU2005295269B2 (en) 2004-10-19 2010-05-13 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
CA2651174A1 (en) * 2006-05-03 2007-11-15 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
EP1878342A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
WO2008051854A2 (en) 2006-10-20 2008-05-02 Trustees Of Boston University A tunable genetic switch for regulating gene expression
JP2008159109A (ja) 2006-12-21 2008-07-10 Matsushita Electric Ind Co Ltd データ転送装置
EP2262898B1 (en) 2008-03-07 2018-01-24 Regeneron Pharmaceuticals, Inc. Es cell-derived mice from diploid host embryo injection
US20090328240A1 (en) 2008-06-24 2009-12-31 Sing George L Genetically modified mice as predictors of immune response
WO2010107400A1 (en) 2009-03-20 2010-09-23 Agency For Science, Technology And Research Genetically modified animal and method of obtaining the same
BR112012000536A2 (pt) * 2009-07-08 2020-08-11 Kymab Limited métodos para produção de anticorpo ou cadeia leve ou pesada de anticorpo específico para um antígeno desejado, para produção de anticorpo ou cadeia de anticorpo e seu uso, composição farmacêutica e derivado de anticorpo quimérico
RU2425880C2 (ru) 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
GB0917090D0 (en) 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
CA2777053A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
KR102203727B1 (ko) 2010-03-31 2021-01-18 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작
JP6482757B2 (ja) 2010-07-26 2019-03-13 トリアンニ インコーポレイテッドＴｒｉａｎｎｉ，Ｉｎｃ． トランスジェニック動物および使用方法
WO2012039779A1 (en) 2010-09-24 2012-03-29 The United States Of America As Represented By The Secretary Of The Navy Humanized transgenic mouse model
CN105950654B (zh) 2010-11-27 2020-03-20 朱坚 一种人源化的转基因动物
CN113349159B (zh) 2015-04-06 2022-11-11 瑞泽恩制药公司 非人动物中的人源化t细胞介导的免疫应答
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002059263A2 (en) * 2000-12-19 2002-08-01 Sunol Molecular Corporation Transgenic animals comprising a humanized immune system
CN104011071A (zh) * 2011-10-28 2014-08-27 瑞泽恩制药公司 T细胞受体基因修饰小鼠
CN107858333A (zh) * 2011-10-28 2018-03-30 瑞泽恩制药公司 T细胞受体基因修饰小鼠

Also Published As

Publication number Publication date
KR20190037354A (ko) 2019-04-05
US20220386575A1 (en) 2022-12-08
JP2020146045A (ja) 2020-09-17
AU2024204645A1 (en) 2024-08-01
EP3424947B1 (en) 2020-11-25
CY1123831T1 (el) 2022-05-27
BR112014009203A2 (pt) 2020-10-27
NZ623147A (en) 2016-03-31
PT2771357T (pt) 2018-11-09
IL305550A (en) 2023-10-01
CN104011071B (zh) 2017-11-07
EP2771357B1 (en) 2018-07-18
IL305550B1 (en) 2024-10-01
EP3424947A1 (en) 2019-01-09
JP2018007696A (ja) 2018-01-18
HK1198171A1 (en) 2015-03-13
KR101964776B1 (ko) 2019-04-04
AU2012327204B2 (en) 2016-01-21
IL232098A0 (en) 2014-05-28
CN104011071A (zh) 2014-08-27
US12582105B2 (en) 2026-03-24
DK3424947T3 (da) 2021-02-22
KR102397961B1 (ko) 2022-05-13
KR20210133325A (ko) 2021-11-05
SMT202100243T1 (it) 2021-05-07
CN114891798A (zh) 2022-08-12
IN2014CN03890A (https=) 2015-10-16
CY1120945T1 (el) 2019-12-11
JP6254528B2 (ja) 2017-12-27
JP6706311B2 (ja) 2020-06-03
IL305550B2 (en) 2025-02-01
PT3424947T (pt) 2021-03-01
PL3424947T3 (pl) 2021-06-14
ES2858978T3 (es) 2021-09-30
RS61455B1 (sr) 2021-03-31
SG11201401030WA (en) 2014-04-28
RU2661106C2 (ru) 2018-07-11
DK2771357T3 (en) 2018-10-29
RS57893B1 (sr) 2019-01-31
JP6532924B2 (ja) 2019-06-19
KR20200102001A (ko) 2020-08-28
JP7656580B2 (ja) 2025-04-03
IL274914B1 (en) 2023-10-01
IL274914B2 (en) 2024-02-01
AU2016202512A1 (en) 2016-05-12
CN107858333A (zh) 2018-03-30
AU2012327204A1 (en) 2013-05-23
KR102148387B1 (ko) 2020-08-26
JP2022093637A (ja) 2022-06-23
AU2021203192A1 (en) 2021-06-10
MX2014004894A (es) 2014-09-12
EP2771357A1 (en) 2014-09-03
AU2021203192B2 (en) 2024-04-11
US9113616B2 (en) 2015-08-25
WO2013063361A1 (en) 2013-05-02
IL315445A (en) 2024-11-01
KR20140077219A (ko) 2014-06-23
HRP20181626T1 (hr) 2018-12-14
PL2771357T3 (pl) 2018-12-31
LT3424947T (lt) 2021-03-10
KR20220066197A (ko) 2022-05-23
CA2853707A1 (en) 2013-05-02
US11528895B2 (en) 2022-12-20
JP2014532413A (ja) 2014-12-08
HUE053444T2 (hu) 2021-06-28
AU2016202512C1 (en) 2018-10-11
MX379517B (es) 2025-03-10
US20210051930A1 (en) 2021-02-25
US20160021856A1 (en) 2016-01-28
CN114891797A (zh) 2022-08-12
IL232098B (en) 2020-06-30
JP2019033770A (ja) 2019-03-07
JP7305840B2 (ja) 2023-07-10
ES2691475T3 (es) 2018-11-27
CN107858332A (zh) 2018-03-30
US20130109053A1 (en) 2013-05-02
CN107858333B (zh) 2022-05-27
RU2014121160A (ru) 2015-12-10
LT2771357T (lt) 2018-10-25
SI3424947T1 (sl) 2021-04-30
SMT201800553T1 (it) 2018-11-09
IL274914A (en) 2020-07-30
MX353134B (es) 2017-12-20
EP3795587A1 (en) 2021-03-24
KR102321909B1 (ko) 2021-11-05
AU2018204700A1 (en) 2018-07-19
SG10201914043XA (en) 2020-03-30
SI2771357T1 (sl) 2018-11-30
AU2018204700C1 (en) 2021-10-14
AU2016202512B2 (en) 2018-03-29
AU2018204700B2 (en) 2021-04-01
KR102542272B1 (ko) 2023-06-13
BR112014009203B1 (pt) 2023-02-28
JP2024019646A (ja) 2024-02-09
HRP20210256T1 (hr) 2021-04-02
JP2023024744A (ja) 2023-02-16

Similar Documents

Publication Publication Date Title
CN114891798B (zh) T细胞受体基因修饰小鼠
HK40049273A (en) Genetically modified t cell receptor mice
HK40002846A (en) Genetically modified t cell receptor mice
HK40002846B (en) Genetically modified t cell receptor mice
HK1198171B (en) Genetically modified t cell receptor mice

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant